June 15, 2009 (FinancialWire) — Hollis-Eden Pharmaceuticals, Inc.’s (NASDAQ: HEPH) (Current Market Cap: $15.54 Mil.) board has appointed James M. Frincke as president and CEO of the company. Frincke was also elected to the company’s board.

Frincke joined Hollis-Eden as vice president of research and development in 1997, was promoted to EVP in 1999, and to chief scientific officer in 2001. He joined Hollis-Eden from Prolinx, where he served as VP of therapeutics research and development from 1995 to 1997.

San Diego-based Hollis-Eden Pharmaceuticals is developing a series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands.

The company’s clinical drug development candidates include Triolex, a compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and Apoptone, a compound in a clinical trial for the treatment of late-stage prostate cancer.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.